Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Dexamethasone"" wg kryterium: Temat


Tytuł :
[Association between high-dose steroid therapy, respiratory function, and time to discharge in patients with COVID-19: Cohort study].
Autorzy :
Rodríguez-Molinero A; Àrea de Recerca, Consorci Sanitari de l'Alt Penedès i Garraf, Sant Pere de Ribes, Barcelona, España. Electronic address: .
Pérez-López C; Technical Research Centre for Dependency Care and Autonomous Living(CETpD), Universitat Politècnica de Catalunya, Vilanova i la Geltrú, Barcelona, España.
Gálvez-Barrón C; Àrea de Recerca, Consorci Sanitari de l'Alt Penedès i Garraf, Sant Pere de Ribes, Barcelona, España.
Miñarro A; Departament de Genètica, Microbiologia i Estadística, Facultat de Biologia, Universitat de Barcelona, Barcelona, España.
Rodríguez Gullello EA; Àrea de Recerca, Consorci Sanitari de l'Alt Penedès i Garraf, Sant Pere de Ribes, Barcelona, España.
Collado Pérez I; Àrea de Recerca, Consorci Sanitari de l'Alt Penedès i Garraf, Sant Pere de Ribes, Barcelona, España.
Milà Ràfols N; Àrea de Recerca, Consorci Sanitari de l'Alt Penedès i Garraf, Sant Pere de Ribes, Barcelona, España.
Mónaco EE; Àrea de Recerca, Consorci Sanitari de l'Alt Penedès i Garraf, Sant Pere de Ribes, Barcelona, España.
Hidalgo García A; Àrea de Recerca, Consorci Sanitari de l'Alt Penedès i Garraf, Sant Pere de Ribes, Barcelona, España.
Añaños Carrasco G; Àrea de Recerca, Consorci Sanitari de l'Alt Penedès i Garraf, Sant Pere de Ribes, Barcelona, España.
Chamero Pastilla A; Àrea de Recerca, Consorci Sanitari de l'Alt Penedès i Garraf, Sant Pere de Ribes, Barcelona, España.
Pokaż więcej
Transliterated Title :
Asociación entre el tratamiento esteroideo a dosis alta, la función respiratoria y el tiempo hasta el alta en pacientes con COVID-19: Estudio de cohortes.
Corporate Authors :
en representación del grupo de investigadores para la COVID-19 del Consorci Sanitari de l’Alt Penedès i Garraf (CSAPG)
Źródło :
Medicina clinica [Med Clin (Barc)] 2021 Jan 08; Vol. 156 (1), pp. 7-12. Date of Electronic Publication: 2020 Sep 25.
Typ publikacji :
Journal Article; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Anti-Inflammatory Agents/*administration & dosage
COVID-19/*drug therapy
Dexamethasone/*administration & dosage
Length of Stay/*statistics & numerical data
Methylprednisolone/*administration & dosage
Oxygen/*metabolism
Adult ; Aged ; Aged, 80 and over ; Anti-Inflammatory Agents/therapeutic use ; Biomarkers/metabolism ; COVID-19/metabolism ; COVID-19/physiopathology ; Dexamethasone/therapeutic use ; Dose-Response Relationship, Drug ; Female ; Follow-Up Studies ; Humans ; Kaplan-Meier Estimate ; Male ; Methylprednisolone/therapeutic use ; Middle Aged ; Patient Discharge/statistics & numerical data ; Proportional Hazards Models ; Respiratory Function Tests ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Long-term follow-up of diabetic macular edema treated with dexamethasone implant: a real-life study.
Autorzy :
Mathis T; Service D'Ophtalmologie, Hôpital Universitaire de La Croix-Rousse, Hospices Civils de Lyon, Université Lyon 1, 103, Grande Rue de la Croix-Rousse, 69317, Lyon Cedex 04, France.; Laboratoire UMR-CNRS 5510 Matéis, Université Lyon 1, Villeurbane, France.
Lereuil T; Service D'Ophtalmologie, Hôpital Universitaire de La Croix-Rousse, Hospices Civils de Lyon, Université Lyon 1, 103, Grande Rue de la Croix-Rousse, 69317, Lyon Cedex 04, France.
Abukashabah A; Service D'Ophtalmologie, Hôpital Universitaire de La Croix-Rousse, Hospices Civils de Lyon, Université Lyon 1, 103, Grande Rue de la Croix-Rousse, 69317, Lyon Cedex 04, France.
Voirin N; EPIMOD, 75 route du Mas Vernon, Dompierre Sur Veyle, France.
Sudhalkar A; Alphavision Augenzentrum, Bremerhaven, Germany.; MS Sudhalkar Medical Research Foundation, Baroda, India.
Bilgic A; Alphavision Augenzentrum, Bremerhaven, Germany.
Denis P; Service D'Ophtalmologie, Hôpital Universitaire de La Croix-Rousse, Hospices Civils de Lyon, Université Lyon 1, 103, Grande Rue de la Croix-Rousse, 69317, Lyon Cedex 04, France.
Dot C; Department of Ophthalmology, Desgenettes Military Hospital, Lyon, France.; French Military Health Service Academy of Val-de-Grâce, Paris, France.
Kodjikian L; Service D'Ophtalmologie, Hôpital Universitaire de La Croix-Rousse, Hospices Civils de Lyon, Université Lyon 1, 103, Grande Rue de la Croix-Rousse, 69317, Lyon Cedex 04, France. .; Laboratoire UMR-CNRS 5510 Matéis, Université Lyon 1, Villeurbane, France. .
Pokaż więcej
Źródło :
Acta diabetologica [Acta Diabetol] 2020 Dec; Vol. 57 (12), pp. 1413-1421. Date of Electronic Publication: 2020 Jul 12.
Typ publikacji :
Journal Article; Multicenter Study; Observational Study
MeSH Terms :
Drug Implants*
Dexamethasone/*administration & dosage
Diabetic Retinopathy/*drug therapy
Macular Edema/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Cohort Studies ; Dexamethasone/adverse effects ; Female ; Follow-Up Studies ; Humans ; Intraocular Pressure/drug effects ; Intravitreal Injections ; Macular Edema/etiology ; Male ; Middle Aged ; Retrospective Studies ; Visual Acuity/drug effects
Czasopismo naukowe
Tytuł :
The impact of maintenance therapy on sleep-wake rhythms and cancer-related fatigue in pediatric acute lymphoblastic leukemia.
Autorzy :
Steur LMH; Emma Children's Hospital, Amsterdam UMC, Pediatric Oncology, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, ZH 8D12, P.O. Box 7057, 1007 MB, Amsterdam, The Netherlands. .
Kaspers GJL; Emma Children's Hospital, Amsterdam UMC, Pediatric Oncology, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, ZH 8D12, P.O. Box 7057, 1007 MB, Amsterdam, The Netherlands.; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.; Dutch Childhood Oncology Group, Utrecht, The Netherlands.
van Someren EJW; Department of Sleep and Cognition, Netherlands Institute for Neuroscience (an institute of the Royal Netherlands Academy of Arts and Sciences), Amsterdam, The Netherlands.; Department of Integrative Neurophysiology, Amsterdam Neuroscience, Center for Neurogenomics and Cognitive Research (CNCR), VU University Amsterdam, Amsterdam, The Netherlands.; Psychiatry, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
van Eijkelenburg NKA; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.
van der Sluis IM; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.; Department of Pediatric Oncology, Sophia Children's Hospital, Erasmus Medical Center, Rotterdam, the Netherlands.
Dors N; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.; Department of Pediatric Oncology, Amalia Children's Hospital, Radboud University Medical Center, Nijmegen, the Netherlands.
van den Bos C; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.; Department of Pediatric Oncology, Emma Children's Hospital, Amsterdam UMC, Academic Medical Center, Amsterdam, the Netherlands.
Tissing WJE; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.; Department of pediatric oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Grootenhuis MA; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.
van Litsenburg RRL; Emma Children's Hospital, Amsterdam UMC, Pediatric Oncology, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, ZH 8D12, P.O. Box 7057, 1007 MB, Amsterdam, The Netherlands. .; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands. .
Pokaż więcej
Źródło :
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2020 Dec; Vol. 28 (12), pp. 5983-5993. Date of Electronic Publication: 2020 Apr 13.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents, Hormonal/*adverse effects
Dexamethasone/*adverse effects
Fatigue/*physiopathology
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy
Sleep/*drug effects
Sleep Wake Disorders/*chemically induced
Actigraphy ; Antineoplastic Agents, Hormonal/therapeutic use ; Child ; Child, Preschool ; Dexamethasone/therapeutic use ; Female ; Humans ; Male ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology ; Sleep Wake Disorders/physiopathology
Czasopismo naukowe
Tytuł :
Effects of antenatal dexamethasone and hyperglycemia on cardiovascular adaptation to asphyxia in preterm fetal sheep.
Autorzy :
Lear CA; The Fetal Physiology and Neuroscience Group, Department of Physiology, The University of Auckland, Auckland, New Zealand.
Davidson JO; The Fetal Physiology and Neuroscience Group, Department of Physiology, The University of Auckland, Auckland, New Zealand.
Dhillon SK; The Fetal Physiology and Neuroscience Group, Department of Physiology, The University of Auckland, Auckland, New Zealand.
King VJ; The Fetal Physiology and Neuroscience Group, Department of Physiology, The University of Auckland, Auckland, New Zealand.
Lear BA; The Fetal Physiology and Neuroscience Group, Department of Physiology, The University of Auckland, Auckland, New Zealand.
Magawa S; The Fetal Physiology and Neuroscience Group, Department of Physiology, The University of Auckland, Auckland, New Zealand.; Department of Obstetrics and Gynecology, Mie University, Mie, Japan.
Maeda Y; The Fetal Physiology and Neuroscience Group, Department of Physiology, The University of Auckland, Auckland, New Zealand.; Department of Obstetrics and Gynecology, Mie University, Mie, Japan.
Ikeda T; Department of Obstetrics and Gynecology, Mie University, Mie, Japan.
Gunn AJ; The Fetal Physiology and Neuroscience Group, Department of Physiology, The University of Auckland, Auckland, New Zealand.
Bennet L; The Fetal Physiology and Neuroscience Group, Department of Physiology, The University of Auckland, Auckland, New Zealand.
Pokaż więcej
Źródło :
American journal of physiology. Regulatory, integrative and comparative physiology [Am J Physiol Regul Integr Comp Physiol] 2020 Dec 01; Vol. 319 (6), pp. R653-R665. Date of Electronic Publication: 2020 Oct 14.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Asphyxia Neonatorum/*drug therapy
Blood Glucose/*drug effects
Dexamethasone/*toxicity
Fetal Heart/*drug effects
Glucocorticoids/*toxicity
Hemodynamics/*drug effects
Hyperglycemia/*chemically induced
Premature Birth/*drug therapy
Animals ; Animals, Newborn ; Arterial Pressure/drug effects ; Asphyxia Neonatorum/blood ; Asphyxia Neonatorum/physiopathology ; Biomarkers/blood ; Blood Glucose/metabolism ; Dexamethasone/administration & dosage ; Disease Models, Animal ; Fetal Heart/physiopathology ; Gestational Age ; Glucocorticoids/administration & dosage ; Heart Rate/drug effects ; Hyperglycemia/blood ; Hyperglycemia/physiopathology ; Premature Birth/blood ; Premature Birth/physiopathology ; Sheep, Domestic ; Time Factors
Czasopismo naukowe
Tytuł :
Analgesic effect of intravenous dexamethasone after volar plate surgery for distal radius fracture with brachial plexus block anaesthesia: a prospective, double-blind randomised clinical trial
Autorzy :
Holmberg A; Department of Anaesthesiology, Oslo University Hospital, Oslo, Norway.
Hassellund SS; Department of Orthopaedic Surgery, Oslo University Hospital, Oslo, Norway.
Draegni T; Department of Research and Development, Division of Emergencies and Critical Care, Oslo University Hospital, Oslo, Norway.
Nordby A; Department of Anaesthesiology, Oslo University Hospital, Oslo, Norway.
Ottesen FS; Department of Anaesthesiology, Oslo University Hospital, Oslo, Norway.
Gulestøl A; Department of Anaesthesiology, Oslo University Hospital, Oslo, Norway.
Raeder J; Department of Anaesthesiology, Oslo University Hospital, Oslo, Norway.; Faculty of Medicine, University of Oslo, Norway.
Pokaż więcej
Źródło :
Anaesthesia [Anaesthesia] 2020 Nov; Vol. 75 (11), pp. 1448-1460. Date of Electronic Publication: 2020 May 30.
Typ publikacji :
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Analgesia/*methods
Brachial Plexus Block/*methods
Dexamethasone/*pharmacology
Glucocorticoids/*pharmacology
Palmar Plate/*surgery
Radius Fractures/*surgery
Administration, Intravenous ; Adult ; Dexamethasone/administration & dosage ; Double-Blind Method ; Female ; Glucocorticoids/administration & dosage ; Humans ; Male ; Middle Aged ; Prospective Studies ; Young Adult
Czasopismo naukowe
Tytuł :
Isoimperatorin reduces the effective dose of dexamethasone in a murine model of asthma by inhibiting mast cell activation.
Autorzy :
Wang J; College of Pharmacy, Xi'an Jiaotong University, Xi'an, China.
Zhang Y; College of Pharmacy, Xi'an Jiaotong University, Xi'an, China.
Zeng Y; College of Pharmacy, Xi'an Jiaotong University, Xi'an, China.
Ge S; College of Pharmacy, Xi'an Jiaotong University, Xi'an, China.
Sun X; Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Jia M; Institute of Basic and Translational Medicine, Xi'an Medical University, Xi'an, China.
Wu Y; Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Wang N; College of Pharmacy, Xi'an Jiaotong University, Xi'an, China.
Pokaż więcej
Źródło :
Phytotherapy research : PTR [Phytother Res] 2020 Nov; Vol. 34 (11), pp. 2985-2997. Date of Electronic Publication: 2020 Jun 03.
Typ publikacji :
Journal Article
MeSH Terms :
Asthma/*drug therapy
Dexamethasone/*therapeutic use
Furocoumarins/*therapeutic use
Mast Cells/*drug effects
Animals ; Dexamethasone/pharmacology ; Disease Models, Animal ; Furocoumarins/pharmacology ; Humans ; Mice
Czasopismo naukowe
Tytuł :
Dexamethasone therapy in COVID-19 patients: implications and guidance for the management of blood glucose in people with and without diabetes.
Autorzy :
Rayman G; The Ipswich Diabetes Centre, East Suffolk and North Essex NHS Foundation Trust, Colchester.
Lumb AN; Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford.
Kennon B; Department of Diabetes, Queen Elizabeth University Hospital, Glasgow.
Cottrell C; Swansea Bay University Health Board, Port Talbot.
Nagi D; Mid Yorkshire Hospital NHS Trust, Wakefield.
Page E; Diabetes Centre, Ipswich Hospital NHS Trust, Ipswich.
Voigt D; Ninewells Hospital, NHS Tayside, Dundee.
Courtney HC; Belfast Health and Social Care Trust, Belfast.
Atkins H; University Hospitals of Leicester NHS Trust, Leicester.
Higgins K; University Hospitals of Leicester NHS Trust, Leicester.
Platts J; Cardiff and Vale University Health Board, Cardiff.
Dhatariya K; Diabetes Centre, Norfolk & Norwich University Hospital NHS Trust, Norwich.
Patel M; University Hospital Southampton NHS Foundation Trust, Southampton.
Newland-Jones P; University Hospital Southampton NHS Foundation Trust, Southampton.
Narendran P; Queen Elizabeth Hospital Birmingham, Birmingham.
Kar P; NHS Diabetes Programme, NHS England.
Burr O; Diabetes UK.
Thomas S; Diabetes Centre King's College Hospital, London.
Stewart R; Gladstone Centre, Wrexham Maelor Hospital, Wrexham, UK.
Pokaż więcej
Źródło :
Diabetic medicine : a journal of the British Diabetic Association [Diabet Med] 2021 Jan; Vol. 38 (1), pp. e14378. Date of Electronic Publication: 2020 Sep 21.
Typ publikacji :
Letter
MeSH Terms :
SARS-CoV-2*
COVID-19/*drug therapy
Dexamethasone/*administration & dosage
Diabetes Mellitus/*drug therapy
Diabetes Mellitus/*epidemiology
Glycemic Control/*methods
COVID-19/epidemiology ; Comorbidity ; Dexamethasone/adverse effects ; Humans ; Hypoglycemia/chemically induced ; Hypoglycemia/prevention & control ; Insulin, Isophane/administration & dosage
Opinia redakcyjna
Tytuł :
Pragmatic trials with prespecified subgroups: what oncologists can learn from COVID-19.
Autorzy :
Banerjee R; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
Prasad V; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA. .; Department of Epidemiology and Biostatistics, Department of Medicine, University of California San Francisco, San Francisco, CA, USA. .; Department of Hematology Oncology, San Francisco General Hospital, San Francisco, CA, USA. .
Pokaż więcej
Źródło :
Nature reviews. Clinical oncology [Nat Rev Clin Oncol] 2021 Jan; Vol. 18 (1), pp. 7-8.
Typ publikacji :
Journal Article; Comment
MeSH Terms :
COVID-19*/drug therapy
Dexamethasone*/therapeutic use
Anti-Inflammatory Agents/therapeutic use ; Humans ; Inpatients ; Oncologists ; SARS-CoV-2
SCR Protocol :
COVID-19 drug treatment
Czasopismo naukowe
Tytuł :
Gestational exposure to excessive levels of dexamethasone impairs maternal care and impacts on the offspring's survival in rats.
Autorzy :
Cella EC; Departamento de Ciências Fisiológicas, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina - UFSC, Florianópolis, SC, Brazil; Programa de Pós-Graduação Multicêntrico em Ciências Fisiológicas, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina - UFSC, Campus, Florianópolis, SC, Brazil.
Conte J; Departamento de Ciências Fisiológicas, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina - UFSC, Florianópolis, SC, Brazil.
Stolte RCK; Departamento de Ciências Fisiológicas, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina - UFSC, Florianópolis, SC, Brazil.
Lorenzon F; Departamento de Ciências Fisiológicas, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina - UFSC, Florianópolis, SC, Brazil; Programa de Pós-Graduação Multicêntrico em Ciências Fisiológicas, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina - UFSC, Campus, Florianópolis, SC, Brazil.
Gregorio T; Departamento de Ciências Fisiológicas, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina - UFSC, Florianópolis, SC, Brazil; Programa de Pós-Graduação Multicêntrico em Ciências Fisiológicas, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina - UFSC, Campus, Florianópolis, SC, Brazil.
Simas BB; Departamento de Ciências Fisiológicas, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina - UFSC, Florianópolis, SC, Brazil.
Rafacho A; Departamento de Ciências Fisiológicas, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina - UFSC, Florianópolis, SC, Brazil; Programa de Pós-Graduação Multicêntrico em Ciências Fisiológicas, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina - UFSC, Campus, Florianópolis, SC, Brazil.
Lima FB; Departamento de Ciências Fisiológicas, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina - UFSC, Florianópolis, SC, Brazil; Programa de Pós-Graduação Multicêntrico em Ciências Fisiológicas, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina - UFSC, Campus, Florianópolis, SC, Brazil. Electronic address: .
Pokaż więcej
Źródło :
Life sciences [Life Sci] 2021 Jan 01; Vol. 264, pp. 118599. Date of Electronic Publication: 2020 Oct 27.
Typ publikacji :
Journal Article
MeSH Terms :
Anti-Inflammatory Agents/*toxicity
Dexamethasone/*toxicity
Maternal Behavior/*drug effects
Prenatal Exposure Delayed Effects/*chemically induced
Prenatal Exposure Delayed Effects/*mortality
Animals ; Animals, Newborn ; Anti-Inflammatory Agents/administration & dosage ; Dexamethasone/administration & dosage ; Female ; Male ; Maternal Behavior/physiology ; Maternal Behavior/psychology ; Pregnancy ; Prenatal Exposure Delayed Effects/psychology ; Rats ; Rats, Wistar ; Survival Rate/trends
Czasopismo naukowe
Tytuł :
Beneath a Tough Mother (Dura Mater) - Chronic Subdural Hematoma.
Autorzy :
Ropper AH
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2020 Dec 31; Vol. 383 (27), pp. 2678-2680. Date of Electronic Publication: 2020 Dec 16.
Typ publikacji :
Editorial; Comment
MeSH Terms :
Anti-Inflammatory Agents*/therapeutic use
Dexamethasone*/therapeutic use
Dura Mater*
Hematoma, Subdural, Chronic*/drug therapy
Humans
Opinia redakcyjna
Tytuł :
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial.
Autorzy :
Kumar SK; Division of Hematology, Mayo Clinic, Rochester, MN, USA. Electronic address: .
Harrison SJ; Clinical Hematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia.
Cavo M; Seragnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.
de la Rubia J; Hematology Service, Dr Peset University Hospital, Valencia, Spain; School of Medicine and Dentistry, Catholic University of Valencia, Valencia, Spain.
Popat R; Department of Haematology, University College London Hospitals, London, UK.
Gasparetto C; School of Medicine, Duke University, Durham, NC, USA.
Hungria V; Clinica São Germano, São Paulo, Brazil.
Salwender H; Department of Hematology-Oncology, Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona and Asklepios Klinik St Georg, Hamburg, Germany.
Suzuki K; Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Kim I; Department of Rehabilitation Medicine, Seoul National University, Seoul, South Korea.
Punnoose EA; Oncology Biomarker Development, Product Development, Hemtology, Genentech, South San Francisco, CA, USA.
Hong WJ; Oncology Biomarker Development, Product Development, Hemtology, Genentech, South San Francisco, CA, USA.
Freise KJ; Research and Development, AbbVie, North Chicago, IL, USA.
Yang X; Research and Development, AbbVie, North Chicago, IL, USA.
Sood A; Research and Development, AbbVie, North Chicago, IL, USA.
Jalaluddin M; Research and Development, AbbVie, North Chicago, IL, USA.
Ross JA; Research and Development, AbbVie, North Chicago, IL, USA.
Ward JE; Research and Development, AbbVie, North Chicago, IL, USA.
Maciag PC; Research and Development, AbbVie, North Chicago, IL, USA.
Moreau P; Department of Hematology, University Hospital, Nantes, France.
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2020 Dec; Vol. 21 (12), pp. 1630-1642. Date of Electronic Publication: 2020 Oct 29.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Bortezomib/*administration & dosage
Bridged Bicyclo Compounds, Heterocyclic/*administration & dosage
Dexamethasone/*administration & dosage
Multiple Myeloma/*drug therapy
Proteasome Inhibitors/*administration & dosage
Sulfonamides/*administration & dosage
Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bortezomib/adverse effects ; Bridged Bicyclo Compounds, Heterocyclic/adverse effects ; Dexamethasone/adverse effects ; Double-Blind Method ; Female ; Humans ; Male ; Middle Aged ; Multiple Myeloma/mortality ; Multiple Myeloma/pathology ; Progression-Free Survival ; Proteasome Inhibitors/adverse effects ; Sulfonamides/adverse effects ; Time Factors
Czasopismo naukowe
Tytuł :
Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties.
Autorzy :
Matthay MA; Cardiovascular Research Institute, Departments of Medicine and Anesthesia, University of California, San Francisco, CA 94143, USA. Electronic address: .
Thompson BT; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Pokaż więcej
Źródło :
The Lancet. Respiratory medicine [Lancet Respir Med] 2020 Dec; Vol. 8 (12), pp. 1170-1172. Date of Electronic Publication: 2020 Oct 29.
Typ publikacji :
Journal Article
MeSH Terms :
COVID-19/*drug therapy
Dexamethasone/*administration & dosage
Glucocorticoids/*administration & dosage
Dexamethasone/adverse effects ; Glucocorticoids/adverse effects ; Humans ; Pandemics ; Pragmatic Clinical Trials as Topic ; SARS-CoV-2
Czasopismo naukowe
Tytuł :
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
Autorzy :
Tacchetti P; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Azienda Ospedaliero-Universitaria di Bologna, Università di Bologna, Bologna, Italy.
Pantani L; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Azienda Ospedaliero-Universitaria di Bologna, Università di Bologna, Bologna, Italy.
Patriarca F; Clinical Hematology and Bone Marrow Transplant Centre, S Maria della Misericordia University Hospital, DAME, University of Udine, Udine, Italy.
Petrucci MT; Hematology Unit, and Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.
Zamagni E; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Azienda Ospedaliero-Universitaria di Bologna, Università di Bologna, Bologna, Italy.
Dozza L; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Azienda Ospedaliero-Universitaria di Bologna, Università di Bologna, Bologna, Italy.
Galli M; Hematology and Bone Marrow Transplant Unit, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.
Di Raimondo F; Division of Hematology, Azienda Ospedaliero-Universitaria Policlinico, Department of Surgery and Medical Specialties, University of Catania, Catania, Italy.
Crippa C; Unità Operativa Complessa di Ematologia, Spedali Civili Brescia, Brescia, Italy.
Boccadoro M; Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Cittàdella Salute e della Scienza, Turin, Italy.
Barbato S; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Azienda Ospedaliero-Universitaria di Bologna, Università di Bologna, Bologna, Italy.
Tosi P; Unità Operativa, Ematologia, Ospedale Infermi di Rimini, Rimini, Italy.
Narni F; Programma Trapianti Cellule Staminali Emopoietiche, Università di Modena e Reggio Emilia, Azienda Ospedaliero-Universitaria, Policlinico di Modena, Modena, Italy.
Montefusco V; Department of Hematology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Testoni N; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Azienda Ospedaliero-Universitaria di Bologna, Università di Bologna, Bologna, Italy.
Spadano A; Unità Operativa Complessa, Ematologia Clinica, Azienda Sanitaria Locale di Pescara, Pescara, Italy.
Terragna C; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Azienda Ospedaliero-Universitaria di Bologna, Università di Bologna, Bologna, Italy.
Pescosta N; Reparto di Ematologia e Centro Trapianto Midollo Osseo, Ospedale Centrale, Bolzano, Italy.
Marzocchi G; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Azienda Ospedaliero-Universitaria di Bologna, Università di Bologna, Bologna, Italy.
Cellini C; Unità Operativa Complessa Ematologia, Ospedale Santa Maria delle Croci, Ravenna, Italy.
Galieni P; Unità Operativa Complessa Ematologia e Terapia cellulare, Ospedale Costanzo e Giacomo Mazzoni, Ascoli Piceno, Italy.
Ronconi S; IRCCS, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy.
Gobbi M; Dipartimento di Medicina interna, Clinica Ematologica, Policlinico Ospedale San Martino, Genoa, Italy.
Catalano L; Unità Operativa Ematologia, Azienda Ospedaliero-Universitaria Federico II, Napoli, Italy.
Lazzaro A; Division of Hematology and Bone Marrow Transplant Center, Department of Oncology-Hematology, Guglielmo da Saliceto Hospital, Piacenza, Italy.
De Sabbata G; Struttura Complessa Ematologia, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy.
Cangialosi C; Divisione di Ematologia ad indirizzo oncologico con Trapianto, Azienda Ospedali Riuniti 'Villa Sofia Cervello', Presidio Ospedaliero 'V Cervello', Palermo, Italy.
Ciambelli F; Struttura Complessa di Ematologia, Azienda Socio Sanitaria Territoriale della Valle Olona, Busto Arsizio, Italy.
Musto P; 'Aldo Moro' University School of Medicine, Unit of Hematology and Stem Cell Transplantation, AOUCPoliclinico, Bari, Italy; Unit of Hematology and Stem Cell Transplantation, Istituto di Ricovero e Cura a Carattere Scientifico Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy.
Elice F; Department of Cell Therapy and Hematology, San Bortolo Hospital, Vicenza, Italy.
Cavo M; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Azienda Ospedaliero-Universitaria di Bologna, Università di Bologna, Bologna, Italy. Electronic address: .
Pokaż więcej
Corporate Authors :
GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto Italian Myeloma Network)
Źródło :
The Lancet. Haematology [Lancet Haematol] 2020 Dec; Vol. 7 (12), pp. e861-e873.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Bortezomib/*therapeutic use
Dexamethasone/*therapeutic use
Hematopoietic Stem Cell Transplantation/*methods
Multiple Myeloma/*drug therapy
Multiple Myeloma/*therapy
Thalidomide/*therapeutic use
Transplantation Conditioning/*methods
Transplantation, Autologous/*methods
Adolescent ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Bortezomib/pharmacology ; Dexamethasone/pharmacology ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Multiple Myeloma/pathology ; Thalidomide/pharmacology ; Young Adult
Czasopismo naukowe
Tytuł :
Outcome of COVID-19 in multiple myeloma patients in relation to treatment.
Autorzy :
Susek KH; Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institute, Stockholm, Sweden.
Gran C; Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institute, Stockholm, Sweden.; Department of Clinical Chemistry, Karolinska University Laboratory, Stockholm, Sweden.
Ljunggren HG; Center for Infectious Medicine, Department of Medicine, Karolinska Institute, Stockholm, Sweden.
Alici E; Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institute, Stockholm, Sweden.; Hematology Center, Karolinska University Hospital, Stockholm, Sweden.
Nahi H; Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institute, Stockholm, Sweden.; Hematology Center, Karolinska University Hospital, Stockholm, Sweden.
Pokaż więcej
Źródło :
European journal of haematology [Eur J Haematol] 2020 Dec; Vol. 105 (6), pp. 751-754. Date of Electronic Publication: 2020 Aug 18.
Typ publikacji :
Journal Article
MeSH Terms :
Antibodies, Monoclonal/*adverse effects
Antineoplastic Combined Chemotherapy Protocols/*adverse effects
Coronavirus Infections/*diagnosis
Dexamethasone/*adverse effects
Lenalidomide/*adverse effects
Multiple Myeloma/*diagnosis
Pneumonia, Viral/*diagnosis
Thalidomide/*adverse effects
Antibodies, Monoclonal/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Betacoronavirus/pathogenicity ; COVID-19 ; Cohort Studies ; Coronavirus Infections/drug therapy ; Coronavirus Infections/immunology ; Coronavirus Infections/mortality ; Dexamethasone/administration & dosage ; Disease Progression ; Female ; Humans ; Immunomodulation ; Lenalidomide/administration & dosage ; Male ; Middle Aged ; Multiple Myeloma/drug therapy ; Multiple Myeloma/immunology ; Multiple Myeloma/mortality ; Pandemics ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/immunology ; Pneumonia, Viral/mortality ; Prognosis ; Remission Induction ; SARS-CoV-2 ; Severity of Illness Index ; Survival Analysis ; Thalidomide/administration & dosage ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial.
Autorzy :
Roussel M; Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.
Moreau P; Hematology, University Hospital Hôtel-Dieu, Nantes, France.
Hebraud B; Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.
Laribi K; Centre Hospitalier, Le Mans, France.
Jaccard A; Centre Hospitalier Universitaire de Limoges, Limoges, France.
Dib M; Centre Hospitalier Régional Universitaire-Hôpital du Bocage, Angers, France.
Slama B; Centre Hospitalier H Duffaut, Avignon, France.
Dorvaux V; Hôpital de Mercy (Centre Hospitalier Régional Metz-Thionville), Metz, France.
Royer B; Hôpital St-Louis, Paris, France.
Frenzel L; Hôpital Necker, Paris, France.
Zweegman S; Amsterdam Universitair Medische Centra, Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam, Netherlands.
Klein SK; Meander Medical Centre, Amersfoort, Netherlands.
Broijl A; Erasmus MC Cancer Institute, Rotterdam, Netherlands.
Jie KS; Zuyderland MC, Sittard, Netherlands.
Wang J; Janssen Global Services, Raritan, NJ, USA.
Vanquickelberghe V; Janssen Research and Development, Beerse, Belgium.
de Boer C; Janssen Research and Development, Leiden, Netherlands.
Kampfenkel T; Janssen Research and Development, Leiden, Netherlands.
Gries KS; Janssen Global Services, Raritan, NJ, USA.
Fastenau J; Janssen Global Services, Raritan, NJ, USA.
Sonneveld P; Erasmus MC Cancer Institute, Rotterdam, Netherlands. Electronic address: .
Pokaż więcej
Źródło :
The Lancet. Haematology [Lancet Haematol] 2020 Dec; Vol. 7 (12), pp. e874-e883.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
MeSH Terms :
Antibodies, Monoclonal/*therapeutic use
Bortezomib/*therapeutic use
Dexamethasone/*therapeutic use
Multiple Myeloma/*drug therapy
Quality of Life/*psychology
Thalidomide/*therapeutic use
Antibodies, Monoclonal/pharmacology ; Antineoplastic Combined Chemotherapy Protocols ; Bortezomib/pharmacology ; Dexamethasone/pharmacology ; Female ; Humans ; Male ; Thalidomide/pharmacology
Czasopismo naukowe
Tytuł :
High-dose dexamethasone plus recombinant human thrombopoietin vs high-dose dexamethasone alone as frontline treatment for newly diagnosed adult primary immune thrombocytopenia: A prospective, multicenter, randomized trial.
Autorzy :
Yu Y; Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Wang M; Department of Pediatrics, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Hou Y; Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Qin P; Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Zeng Q; Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Yu W; Department of Hematology, Binzhou Medical University Hospital, Binzhou, China.
Guo X; Department of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Wang J; Department of Hematology, Liaocheng People's Hospital, Liaocheng, China.
Wang X; Department of Hematology, Xinjiang Uiger Municipal People's Hospital, Urumqi, China.
Liu G; Department of Hematology, Shengli Oilfield Central Hospital, Dongying, China.
Chu X; Department of Hematology, Yantai Yuhuangding Hospital, Yantai, China.
Yang L; Department of Hematology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Feng Y; Department of Hematology, The Second Affiliated Hospital of Guangzhou Medical University, Guangdong, China.
Zhou F; Department of Hematology, Military General Hospital, Jinan, China.
Sun Z; Department of Hematology, Taian City Central Hospital, Taian, China.
Zhang M; Department of Hematology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Wang X; Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
Wang Z; Department of Hematology, Zibo Central Hospital, Zibo, China.
Ran X; Department of Hematology, Weifang People's Hospital, Weifang, China.
Zhao H; Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Wang L; Department of Hematology, Qingdao Municipal Hospital, Qingdao, China.
Zhang H; Department of Hematology, Linyi People's Hospital, Linyi, China.
Bi K; Department of Hematology, Shandong Provincial Qianfoshan Hospital, Jinan, China.
Li D; Department of Hematology, Jinan Central Hospital, Jinan, China.
Yuan C; Department of Hematology, Qilu Hospital (Qingdao), Shandong University, Qingdao, China.
Xu R; Department of Hematology, Shandong Provincial Hospital of Traditional Chinese Medicine, Jinan, China.
Wang Y; Department of Hematology, Weihai Municipal Hospital, Weihai, China.
Zhou Y; Department of Hematology, Zhejiang Provincial Hospital of TCM, Hangzhou, China.
Peng J; Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Liu XG; Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Hou M; Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.; Shandong Province Key Laboratory of Hematology/Immunology, Creative Studio of Scientific and Technologic Leading Talents, Qilu Hospital, Shandong University, Jinan, China.
Pokaż więcej
Źródło :
American journal of hematology [Am J Hematol] 2020 Dec; Vol. 95 (12), pp. 1542-1552. Date of Electronic Publication: 2020 Oct 19.
Typ publikacji :
Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Purpura, Thrombocytopenic, Idiopathic*/drug therapy
Purpura, Thrombocytopenic, Idiopathic*/mortality
Dexamethasone/*administration & dosage
Thrombopoietin/*administration & dosage
Adult ; Aged ; Dexamethasone/adverse effects ; Disease-Free Survival ; Drug Therapy, Combination ; Female ; Humans ; Male ; Middle Aged ; Prospective Studies ; Survival Rate ; Thrombopoietin/adverse effects
Czasopismo naukowe
Tytuł :
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Autorzy :
Grosicki S; Medical University of Silesia, Katowice, Poland. Electronic address: .
Simonova M; Institute of Blood Pathology and Transfusion Medicine, National Academy of Medical Sciences of Ukraine, Lviv, Ukraine.
Spicka I; Charles University and General Hospital, Prague, Czech Republic.
Pour L; Clinic of Internal Medicine-Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.
Kriachok I; National Cancer Institute Ukraine, Kiev, Ukraine.
Gavriatopoulou M; Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Pylypenko H; Department of Hematology, Cherkassy Regional Oncological Center, Cherkassy, Ukraine.
Auner HW; Imperial College London, London, UK.
Leleu X; Department of Hematology, CHU la Miletrie and Inserm CIC 1402, Poitiers, France.
Doronin V; City Clinical Hospital No. 40, Moscow, Russia.
Usenko G; City Clinical Hospital 4 of Dnipro City Council, City Hematology Center, Dnipro, Ukraine.
Bahlis NJ; Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada.
Hajek R; Department of Hemato-oncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
Benjamin R; Kings College NHS Foundation Trust, Kings College London, London, UK.
Dolai TK; Nil Ratan Sircar Medical College and Hospital, Kolkata, India.
Sinha DK; State Cancer Institute, Indira Gandhi Institute of Medical Sciences, Patna, India.
Venner CP; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
Garg M; University Hospitals of Leicester NHS Trust, Leicester, UK.
Gironella M; Vall d'Hebron University Hospital, Barcelona, Spain.
Jurczyszyn A; Department of Hematology, Jagiellonian University Medical College, Kraków, Poland.
Robak P; Department of Hematology, Copernicus Memorial Hospital, Medical University of Lodz, Lodz, Poland.
Galli M; Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy.
Wallington-Beddoe C; Flinders Medical Centre and Flinders University, Adelaide, SA, Australia.
Radinoff A; University Hospital 'St Ivan Rilski' EAD, Sofia, Bulgaria.
Salogub G; Chemotherapy of Oncology Diseases-Bone Marrow Transplantation Department 1, Almazov National Medical Research Centre, Ministry of Health of Russia, St Petersburg, Russia.
Stevens DA; Norton Cancer Institute, St Matthews Campus, Louisville, KY, USA.
Basu S; New Cross Hospital, Royal Wolverhampton NHS Trust and University of Wolverhampton, Wolverhampton, UK.
Liberati AM; Oncohematology Hospital S Maria Terni, University of Perugia, Terni, Italy.
Quach H; University of Melbourne, St Vincent's Hospital, Melbourne, VIC, Australia.
Goranova-Marinova VS; University Hospital 'Sv Georgi' EAD, Clinic of Clinical Hematology, Medical University of Plovdiv, Plovdiv, Bulgaria.
Bila J; Clinic for Hematology, Clinical Centre of Serbia, Belgrade, Serbia.
Katodritou E; Hematology Department, Theagenion Cancer Hospital, Thessaloniki, Greece.
Oliynyk H; Department of Hematology, Vinnytsia M I Pyrohov Regional Clinical Hospital, Vinnytsia, Ukraine.
Korenkova S; Bone Marrow Transplantation Department, Kyiv Bone Marrow Transplantation Center, Kyiv, Ukraine.
Kumar J; Tata Medical Center, Kolkata, India.
Jagannath S; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Moreau P; University Hospital, Hotel-Dieu, Nantes, France.
Levy M; Baylor University Medical Center, Dallas, TX, USA.
White D; Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, NS, Canada.
Gatt ME; Hadassah Hebrew University Medical Center, Jerusalem, Israel.
Facon T; CHU Lille Service des Maladies du Sang F-59000, Lille, France.
Mateos MV; Hospital Universitario de Salamanca, Salamanca, Spain.
Cavo M; Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università degli Studi, Bologna, Italy.
Reece D; University Health Network-Princess Margaret Cancer Centre, Toronto, ON, Canada.
Anderson LD Jr; Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Saint-Martin JR; Karyopharm Therapeutics, Newton, MA, USA.
Jeha J; Karyopharm Therapeutics, Newton, MA, USA.
Joshi AA; Karyopharm Therapeutics, Newton, MA, USA.
Chai Y; Karyopharm Therapeutics, Newton, MA, USA.
Li L; Karyopharm Therapeutics, Newton, MA, USA.
Peddagali V; Karyopharm Therapeutics, Newton, MA, USA.
Arazy M; Karyopharm Therapeutics, Newton, MA, USA.
Shah J; Karyopharm Therapeutics, Newton, MA, USA.
Shacham S; Karyopharm Therapeutics, Newton, MA, USA.
Kauffman MG; Karyopharm Therapeutics, Newton, MA, USA.
Dimopoulos MA; School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Richardson PG; Dana-Farber Cancer Institute, Boston, MA, USA.
Delimpasi S; General Hospital Evangelismos, Athens, Greece.
Pokaż więcej
Źródło :
Lancet (London, England) [Lancet] 2020 Nov 14; Vol. 396 (10262), pp. 1563-1573.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents/*administration & dosage
Bortezomib/*administration & dosage
Dexamethasone/*administration & dosage
Hydrazines/*administration & dosage
Multiple Myeloma/*drug therapy
Triazoles/*administration & dosage
Adolescent ; Adult ; Aged ; Antineoplastic Agents/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bortezomib/adverse effects ; Dexamethasone/adverse effects ; Drug Administration Schedule ; Female ; Humans ; Hydrazines/adverse effects ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Progression-Free Survival ; Triazoles/adverse effects
Czasopismo naukowe
Tytuł :
Antenatal Dexamethasone Exposure Impairs the High-Conductance Ca Channels via Epigenetic Alteration at Gene Promoter in Male Offspring.
Autorzy :
Xu T; First Hospital of Soochow University, Institute for Fetology, Suzhou, China.
Zhao M; First Hospital of Soochow University, Institute for Fetology, Suzhou, China.
Li H; First Hospital of Soochow University, Institute for Fetology, Suzhou, China.
Zhou X; First Hospital of Soochow University, Institute for Fetology, Suzhou, China.
Liu B; First Hospital of Soochow University, Institute for Fetology, Suzhou, China.
Sun M; First Hospital of Soochow University, Institute for Fetology, Suzhou, China.
Xu Z; First Hospital of Soochow University, Institute for Fetology, Suzhou, China.
Gao Q; First Hospital of Soochow University, Institute for Fetology, Suzhou, China.
Pokaż więcej
Źródło :
Arteriosclerosis, thrombosis, and vascular biology [Arterioscler Thromb Vasc Biol] 2020 Nov; Vol. 40 (11), pp. e284-e295. Date of Electronic Publication: 2020 Sep 24.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
DNA Methylation*
Epigenesis, Genetic*
Prenatal Exposure Delayed Effects*
Promoter Regions, Genetic*
Dexamethasone/*toxicity
Glucocorticoids/*toxicity
Large-Conductance Calcium-Activated Potassium Channel alpha Subunits/*genetics
Large-Conductance Calcium-Activated Potassium Channel beta Subunits/*genetics
Mesenteric Arteries/*metabolism
Action Potentials ; Animals ; Dexamethasone/administration & dosage ; Female ; Glucocorticoids/administration & dosage ; Large-Conductance Calcium-Activated Potassium Channel alpha Subunits/metabolism ; Large-Conductance Calcium-Activated Potassium Channel beta Subunits/metabolism ; Male ; Maternal Exposure ; Mesenteric Arteries/physiopathology ; Pregnancy ; Rats, Sprague-Dawley ; Vasodilation
Czasopismo naukowe
Tytuł :
Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy.
Autorzy :
Ithimakin S; Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Chalermprakiat Building, 13th floor, Siriraj Hospital, 2 Wanglang Rd, Bangkoknoi, Bangkok, Thailand. .
Theeratrakul P; Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Chalermprakiat Building, 13th floor, Siriraj Hospital, 2 Wanglang Rd, Bangkoknoi, Bangkok, Thailand.
Laocharoenkiat A; Pharmacy Department, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Nimmannit A; Department of Research, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Akewanlop C; Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Chalermprakiat Building, 13th floor, Siriraj Hospital, 2 Wanglang Rd, Bangkoknoi, Bangkok, Thailand.
Soparattanapaisarn N; Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Chalermprakiat Building, 13th floor, Siriraj Hospital, 2 Wanglang Rd, Bangkoknoi, Bangkok, Thailand.
Techawattanawanna S; Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Chalermprakiat Building, 13th floor, Siriraj Hospital, 2 Wanglang Rd, Bangkoknoi, Bangkok, Thailand.
Korphaisarn K; Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Chalermprakiat Building, 13th floor, Siriraj Hospital, 2 Wanglang Rd, Bangkoknoi, Bangkok, Thailand.
Danchaivijitr P; Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Chalermprakiat Building, 13th floor, Siriraj Hospital, 2 Wanglang Rd, Bangkoknoi, Bangkok, Thailand.
Pokaż więcej
Źródło :
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2020 Nov; Vol. 28 (11), pp. 5335-5342. Date of Electronic Publication: 2020 Mar 04.
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
Aprepitant/*therapeutic use
Dexamethasone/*administration & dosage
Nausea/*prevention & control
Olanzapine/*administration & dosage
Ondansetron/*administration & dosage
Vomiting/*prevention & control
Adult ; Aged ; Antiemetics/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Chemoprevention/methods ; Cisplatin/administration & dosage ; Cisplatin/adverse effects ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/adverse effects ; Dexamethasone/adverse effects ; Dose-Response Relationship, Drug ; Double-Blind Method ; Doxorubicin/administration & dosage ; Doxorubicin/adverse effects ; Drug Therapy, Combination ; Emetics/administration & dosage ; Emetics/adverse effects ; Female ; Humans ; Induction Chemotherapy/adverse effects ; Male ; Middle Aged ; Nausea/chemically induced ; Neoplasms/drug therapy ; Neoplasms/pathology ; Olanzapine/adverse effects ; Ondansetron/adverse effects ; Placebos ; Quality of Life ; Treatment Outcome ; Vomiting/chemically induced ; Young Adult
SCR Protocol :
AC protocol
Czasopismo naukowe
Tytuł :
Cataract surgery with combined versus deferred intravitreal dexamethasone implant for diabetic macular edema: long-term outcomes from a real-world setting.
Autorzy :
Corbelli E; Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Via Olgettina 60, 20132, Milan, Italy.
Fasce F; Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Via Olgettina 60, 20132, Milan, Italy.
Iuliano L; Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Via Olgettina 60, 20132, Milan, Italy.
Sacconi R; Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Via Olgettina 60, 20132, Milan, Italy.
Lattanzio R; Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Via Olgettina 60, 20132, Milan, Italy.
Bandello F; Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Via Olgettina 60, 20132, Milan, Italy.
Querques G; Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Via Olgettina 60, 20132, Milan, Italy. .
Pokaż więcej
Źródło :
Acta diabetologica [Acta Diabetol] 2020 Oct; Vol. 57 (10), pp. 1193-1201. Date of Electronic Publication: 2020 May 04.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Cataract Extraction/*methods
Dexamethasone/*administration & dosage
Diabetic Retinopathy/*drug therapy
Diabetic Retinopathy/*surgery
Macular Edema/*drug therapy
Macular Edema/*surgery
Aged ; Cataract/complications ; Cataract/drug therapy ; Cataract Extraction/adverse effects ; Combined Modality Therapy ; Dexamethasone/adverse effects ; Drug Administration Schedule ; Drug Implants ; Female ; Glucocorticoids/administration & dosage ; Glucocorticoids/therapeutic use ; Humans ; Intravitreal Injections ; Macular Edema/complications ; Male ; Middle Aged ; Retrospective Studies ; Time Factors ; Treatment Outcome ; Visual Acuity
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies